Julie Knell

Mylan surges, Teva slumps after FDA approves Copaxone copy Mylan surges, Teva slumps after FDA approves Copaxone copy:- Mylan NV’s long-awaited U.S. approval for its generic version of rival Teva’s blockbuster multiple sclerosis treatment Copaxone drove Mylan’s shares up around 18 percent on Wednesday while Teva shares plunged. The approval […]